Saturday, December 21, 2024
Facebook Linkedin Twitter
HomeTagsLRRK2

LRRK2

Biotechnology

Neuron23 and QIAGEN Announce Collaboration to Develop the Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug

PR Newswire -
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN ( NYSE: QGEN;...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us